Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

Clinical Infectious Diseases

Volumn 34, Issue 11, 2002, Pages 1481-1490

  Stevens, Dennis L ^a,b   Herr, Daniel ^c   Lampiris, Harry ^d,e   Hunt, John Lee ^f   Batts, Donald H ^g   Hafkin, Barry ^g  

^a Boise VA Medical Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; OXAZOLIDINONE DERIVATIVE; VANCOMYCIN;

ADULT; AGED; ARTICLE; BACTERIUM ISOLATE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ACETAMIDES; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 0036604489     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/340353     Document Type: Article

References (55)

1. Epidemiology of methicillin-resistant Staphylococcus aureus
2. Antimicrobial activity, of linezolid (formerly U-100766) tested against 3,808 strains of gram-positive organisms having resistance to various drugs
3. Antimicrobial activity of linezolid (U-100766) tested against 7,599 recent clinical isolates from over 50 medical center laboratories
4. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999
5. Community strain of methicillin-resistant Staphylococcus aureus involved in a hospital outbreak
6. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk
7. Methicillin-resistant Staphylococcus aureus as a community organism
8. The evolving epidemiology of methicillin-resistant Staphylococcus aureus at a university hospital
9. Methicillin-resistant Staphylococcus aureus in tertiary care institutions on the Canadian prairies
10. Community-acquired methicillin-resistant Staphylococcus aureus infections in children
11. Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus
12. Antimicrobial resistance in staphylococci: Epidemiology, molecular mechanisms, and clinical relevance
13. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistances: Real or perceived?
14. Methicillin-resistant Staphylococcus aureus in US hospitals, 1975-1991
15. Methicillin-resistant Staphylococcus aureus in Europe
16. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: At what costs?
17. Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci
18. The economic impact of Staphylococcus aureus infection in New York City hospitals
19. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: A randomized, multicenter trial
20. Determinants of vancomycin use in adult intensive care units in 41 United States hospitals
21. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin
22. Vancomycin in surgical infections to methicillin-resistant Staphylococcus aureus with heterogenous resistance to vancomycin
23. Low-level teicoplanin resistance and heteroresistance to vancomycin
24. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection
25. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance
26. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997
27. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections
28. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials
29. In vitro activities of new oxazolidinone antimicrobial agents against enterococci
30. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections
31. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species
32. In vitro activities of investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium
33. Comparative in vitro activity and postantibiotic effect of oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium
34. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
35. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides
36. Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors
37. Mechanism of action of oxazolidinones: Effect of linezolid and eperezolid on translation reactions
38. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria
39. Linezolid absolute bioavailability and the effect of food on oral bioavailability
40. Linezolid safety, tolerance, and pharmacokinetics following oral dosing twice daily for 14.5 days
41. Linezolid safety, tolerance, and pharmacokinetics after intravenous dosing twice daily for 7.5 days
42. Randomized comparison of linezolid (PNU-100766) versus oxacillin/dicloxacillin for treatment of complicated skin and soft-tissue infections
43. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study
44. Inadequate antimicroblal treatment of infections: A risk factor for hospital mortality among critically ill patients
45. Risk factors for ICU-acquired pneumonia
46. Nosocomial pneumonia on general medical and surgical wards in a tertiary-care hospital
47. Linezolid resistance in a clinical isolate of Staphylococcus aureus
48. Overview of resistance in the 1990s
49. Health and economic impacts of antimicrobial resistance
50. Mortality associated with nosocomlal bacteremia due to methicillin-resistant Staphylococcus aureus
51. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America joint committee on the prevention of antimicrobial resistance: Guidelines for the prevention of antimicrobial resistance in hospitals
52. Bird's-eye view of nosocomial infections in medical ICU: Blue bugs, fungi, and device days
53. Nosocomial infections in medical intensive care units in the United States